HealthQuill Pharma
Pfizer Inc. has signed a licensing deal worth about $6 billion with China’s 3SBio to develop, manufacture and commercialise an experimental cancer drug.
Drugs Health Pharma

Pfizer signs $6 billion licensing deal with China’s 3SBio for cancer drug

HQ Team May 20, 2025: Pfizer Inc. has signed a licensing deal worth about $6 billion with China’s 3SBio to develop, manufacture and.

Read More
The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis.
Drugs Health Pharma

UK clears Janssen-Cilag’s drug for Crohn’s disease, ulcerative colitis

HQ Team May 19, 2025: The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease.

Read More
The UK and Wellcome Trust will invest £600 million to create a new health data research service to accelerate the discovery of life-saving drugs, improve patient care and make Britain “the best place in the world” for medical research.
Drugs Health Pharma

UK, Wellcome to build £600m health data service, fast-pace clinical trials

HQ Team May 19, 2025: The UK and Wellcome Trust will invest £600 million to create a new health data research service to.

Read More
US President Donald Trump’s plan to raise taxes on private philanthropic foundations will harm charities' efforts to provide education, shelter, and food to the country's poor, experts said.
Drugs Health Pharma

US plan to raise taxes on charities a ‘disastrous’ move: Experts say

HQ Team May 19, 2025: US President Donald Trump’s plan to raise taxes on private philanthropic foundations will harm charities’ efforts to provide.

Read More
The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.’s blood test to diagnose Alzheimer’s disease, the first such approval in the country.
Drugs Health Pharma

Simple blood test to detect Alzheimer’s disease gets US regulator’s nod

HQ Team May 18, 2025: The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.’s blood test to diagnose.

Read More
The US regulator is initiating action to remove concentrated ingestible fluoride prescription drug products for children from the market, a move that drew ire from dental experts.
Drugs Health Pharma

US plan to remove ingestible fluoride from children’s drugs draws ire

HQ Team May 14, 2025: The US regulator is initiating action to remove concentrated ingestible fluoride prescription drug products for children from the.

Read More
The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat a specific group of adult lung cancer patients who have tried other systemic treatments.
Drugs Health Pharma

AbbVie’s NSCLC lung cancer drug gets accelerated approval from FDA

 HQ Team May 15, 2025: The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat.

Read More
Harvard University has amended its lawsuit against the US administration by saying that its researchers would lose another $450 million in grants from several agencies.
Health Medical Pharma

Harvard amends lawsuit as federal agencies threaten to cut short grants

HQ Team May 15, 2025: Harvard University has amended its lawsuit against the US administration by saying that its researchers would lose another.

Read More
Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a rare type of tumour in adults and children aged above 12 years, according to a statement.
Drugs Health Pharma

Merck’s pill to treat rare type of tumour gets approval from US regulator

HQ Team May 15, 2025: Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a.

Read More
Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.
Drugs Health Pharma

Novo Nordisk, Septerna in $2.2b deal to develop oral molecules

HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.

Read More